MarketPulse

interstitial lung disease

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Interstitial Lung Disease Market Set to Surge 8.7% Annually Through 2036

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.
BMYCELGrRHHBYGSKUTHR+5FDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Juvenescence Advances PAI-1 Program With Phase 1 Success, Expands Leadership Team

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.
PFEbiotechclinical development